The US FDA has granted emergency use authorization for coronavirus assays from Hologic (MA, USA) and Labcorp (NC, USA). The assays will join those provided by Roche (Basel, Switzerland) and Thermo Fisher Scientific (MA, USA).
Researchers are presenting the details of a new blood-based assay that utilizes cell-free DNA to identify the methylation signals of gastrointestinal cancers at the Gastrointestinal Cancers Symposium, San Francisco, CA, USA, 23–25 January 2020.
Researchers have reported a new blood test that could accurately identify and distinguish active cases of tuberculosis in adults from diseases with similar symptoms in under 1 hour.
This infographic highlights the key qualities to look for in a CRO to ensure the best results when outsourcing immunogenicity assay development and testing.
Thermo Fisher Scientific (MA, USA) have announced a new molecular quality control panel. The panel could provide researchers with increased confidence when performing BCR-ABL assays.
Besides quantitative applications what else can hybrid assay technology do that will be important to future biotherapeutic development?
Question 6: besides quantitative applications what else can hybrid assay technology do that will be important to future biotherapeutic development?
This poster from SCIEX (Warrington, UK) reports the use of an immunoaffinity high-resolution accurate mass assay as a complimentary analytical technique for signature peptide quantification.
LGC (Cambridge, UK) have become the first bioanalytical CRO in Europe to offer the Quanterix Simoa HD-X automated analyzer in a regulated environment.
This infographic highlights tips to overcome challenges in the areas of PK analysis, large molecule analysis by LC–MS/MS and prodrug analysis.
Webinar available to view on demand. This webinar will give an overview of immunogenicity assay development, explore the impact of anti-drug antibodies on bioanalysis and review relevant case studies discussing in-study cut-point and tolerance.